Sentence examples for molecular screening technologies from inspiring English sources

Despite advances in molecular screening technologies, which have spawned new drug targets and therapeutic candidates for neurological diseases, these technologies have yet to find conduits for successful clinical application due in part to disease complexity, the individual variability within the human population and the poor early diagnosis of disease.

While it is widely accepted that the 'molecular gaze' has transformed and reconfigured understandings of the body, semiotics helps us to explicate the nature of the differences between molecular screening technologies and older methods of visualising the internal body.

For these reasons, semiotically informed approaches have the potential to provide new insights into patients' understandings and experiences of molecular screening technologies and to redress the limited analytic scope of much current research into the sociology of screening (see Armstrong and Eborall, 2012).

My goal in this article is to consider the ways in which molecular screening technologies may be impacting the experiences of people with a history of cancer, including both those who have been declared 'disease-free' and those living with active disease.

This empirical work speaks to the growing diseasification of risk that molecular screening technologies facilitate, with risk 'treated' in much the same way as disease itself, through medical means such as medication, behaviour modification and surgical intervention (Armstrong, 1995; Sachs, 1995; Clarke et al, 2003, 2010; Aronowitz, 2009; Sulik, 2011; Gillespie, 2012).

Molecular screening using high-throughput technologies is most likely to benefit patients with metastatic breast cancer because these patients have incurable disease that will eventually become refractory to standard treatments.

The development of regulatory elements, molecular computing devices, and effector screening technologies has enabled researchers to design synthetic gene circuits in many organisms, including mammalian cells.

Technologies, including robust and inexpensive genome sequencing, numerous screening technologies, novel molecular imaging approaches, the ability to work across multiple model systems, and others, have positioned us to make discoveries at a rapid rate.

Recently, many institutions have launched molecular screening programs that apply high-throughput genomic technologies to patients with advanced solid malignancies, including breast cancer, to inform clinical decision-making.

The large allelic and genetic heterogeneity of FH requires high-throughput, rapid, and affordable mutation detection technology to efficiently integrate molecular screening into clinical practice.

We hypothesized that the improvement in early screening technologies, the advent of new molecular targeted agents, and elevated risk of carcinogenesis during the anti-cancer therapy yielded an increase prevalence of second cancer in the individuals ever diagnosed malignancy.